Find where your pharma brand isblurring claims.
Scan any pharma or biotech site through the NES framework. See whether the patient-facing, prescriber-facing, and investor-facing pages tell one coherent story, or whether the gap between them is where the next regulator-letter or analyst flag will find you.
“It separated the patient voice from the prescriber voice from the investor voice in a way the team had not done formally.”
Head of Communications, biotech
Where the indication and the story diverge.
Pharma brands carry the highest discipline cost on claims, audiences, and tone. The scan surfaces where the patient, prescriber, and investor stories stop reinforcing each other.
Are efficacy and indication claims framed in a way that matches the label and the evidence?
Is the site addressing patients, prescribers, payers, and investors with the right voice for each?
Are trial data, label information, and regulatory disclosures placed where doubt rises?
Does the clinical tone match the patient tone match the IR tone, where audiences will eventually compare?
Has the pipeline widened past where the public-facing brand story can carry it?
Does the marketing pace match the regulatory and commercial timeline the company is actually on?
Three uses inside pharma.
Before a quarterly readout, label expansion, or IR cycle. Surfaces inconsistency across audience-facing pages.
Before a campaign or category extension. Sharpens what the team is permitted to say at the brand level.
Before pitching an engagement. Quoted-evidence diagnosis the commercial, medical, and legal sides can all read.
This is not a website opinion. It is a brand consistency diagnosis.
Most AI website audits give broad suggestions: improve the headline, add testimonials, clarify the CTA. The Brand Consistency Scanner is powered by the Net Entropy Score framework, a diagnostic system built to identify where a brand's message, proof, audience, claims, trust signals, and customer promise start drifting apart.
| Generic AI website prompt | NES Brand Consistency Scanner |
|---|---|
| Gives general website feedback | Uses a structured NES diagnostic framework |
| Depends on how good your prompt is | Built around fixed consistency dimensions |
| Often says "improve headline / add proof" | Shows identity confusion, trust leakage, and clarity gaps |
| One-off opinion | Repeatable score and report structure |
| Website-only opinion | Connects to review-inferred and measured customer consistency tiers |
| Hard to compare across brands | Built for competitor comparison and tracking |
Powered by the Net Entropy Score framework. This scan applies NES scoring logic to detect message clarity, identity confusion, trust leakage, brand consistency, and diagnostic confidence.
Same engine. Pharma-tuned read.
Free scan is the website layer. Deeper tiers add written analysis, customer-voice across portals, and measured cohort data.
Fast website-only scan. Surfaces visible clarity, trust, identity, and message gaps in about two minutes.
Human-reviewed deeper read. Audience-architecture map, claim-vs-label review, voice coherence across IR, prescriber, and patient pages with quoted evidence.
Patient and prescriber language across forums, reviews, and condition-specific communities. Shows the gap between marketing promise and lived experience.
Customer-verified consistency measurement using structured cohort survey and the v4.0 NES instrument. Defensible to a board or investor.
Net Entropy Score (NES) v1.0. Working paper: SSRN Abstract 6667158. This Website-Based Brand Consistency Scan is AI-assisted and derived from public website signal pattern recognition on the submitted pages only. Outputs are directional estimates calibrated to the NES framework, not precision forecasts or professional advice. AI systems can make mistakes, miss context, or misinterpret public information. NES, Impossible Marketing, and affiliated operators are not liable for decisions, losses, or actions taken based on this scan. Use this report to open questions and guide further diligence, not as the sole basis for business, investment, legal, financial, or operational decisions. This scan is not a regulatory, medical, or label review and does not constitute clinical, legal, or compliance advice. Claim review must remain the responsibility of qualified clinical, regulatory, and legal counsel.